Paratriathlon

World Lupus Federation Global Survey Finds 91% of People with Lupus Report Using Oral Steroids to Treat Lupus

Retrieved on: 
понедельник, мая 6, 2024
Pain, Inflammation, Patient, Kidney, Weight gain, Risk, Skin, Blood, Heart, Diabetes, Lupus, Insomnia, Paratriathlon, Osteoporosis, Steroid, Joint, Disease, MPH, Infection, Immune system, Prednisone, Pelvic floor dysfunction, Dietary supplement

WASHINGTON, May 6, 2024 /PRNewswire/ -- A recent global survey conducted by the World Lupus Federation reported that 91% of survey respondents were taking or have taken oral steroids to treat their lupus. Over 7,700 people living with lupus from more than 100 countries participated in the survey.

Key Points: 
  • WASHINGTON, May 6, 2024 /PRNewswire/ -- A recent global survey conducted by the World Lupus Federation reported that 91% of survey respondents were taking or have taken oral steroids to treat their lupus.
  • The World Lupus Federation established World Lupus Day on May 10 to unite lupus groups around the world during Lupus Awareness Month and call attention to the disease's impact on the millions of people globally affected by lupus.
  • As we approach World Lupus Day, it is crucial that we continue to advocate for improved access to safe and effective treatments for lupus.
  • The World Lupus Federation is encouraging people around the globe on May 10 for World Lupus Day to share facts about lupus, including from this survey, and raise awareness using the official World Lupus Day Toolkit .

Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024

Retrieved on: 
пятница, мая 3, 2024
AMD, Patient, Abstract (summary), Research, Johnson & Johnson, Collection, Paratriathlon, Abstract, Development, Genetic testing, Retina, Algorithm, Geographic atrophy, Diagnosis, Biomarker, Annual general meeting, ARVO, IRD, Pharmaceutical industry

RARITAN, N.J., May 3, 2024 /PRNewswire/ -- Johnson & Johnson today announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024. The Company's two oral presentations will include one highlighting a real-world analysis on the economic value of early genetic testing in patients with inherited retinal diseases (IRDs), a group of rare eye disorders that can lead to serious vision impairment (Abstract #2154), and the second evaluating the role of automatic deep-learning based algorithms to measure precursors of geographic atrophy (GA), a late-stage and severe form of age-related macular degeneration (AMD) (Abstract #2770).1,2

Key Points: 
  • Johnson & Johnson to debut first-of-its-kind EYE-RD Global Registry, aiming to bridge knowledge gaps for inherited retinal diseases
    RARITAN, N.J., May 3, 2024 /PRNewswire/ -- Johnson & Johnson today announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024.
  • "At Johnson & Johnson, we are committed to preserving vision, harnessing the best science to find solutions for those living with blinding retinal diseases," said Hideo Makimura, M.D., Ph.D., Vice President and Global Head, Specialty Ophthalmology Research and Development, Johnson & Johnson Innovative Medicine.
  • "These data at ARVO 2024 showcase our commitment to bringing innovative new therapies that preserve and restore vision for patients worldwide."
  • A complete listing of the Company-sponsored abstracts being featured at the ARVO Annual Meeting is provided below.

Carrie Naylor Promoted to Office Manager at United Real Estate Strive 212: Setting New Standards

Retrieved on: 
четверг, мая 2, 2024
Caffeine, National Association of Realtors, Perseverance, Office, Mentorship, Visual impairment, Paratriathlon, Real estate agent, Philosophy, Growth

WYOMISSING, Pa., May 2, 2024 /PRNewswire-PRWeb/ -- Carrie Naylor, Office Administrator for United Real Estate Strive 212 has recently been promoted to Office Manager. This achievement comes after working 5 dedicated years with the brokerage as an Administrator despite being visually impaired. Carrie's consistent commitment to the team of Realtors she works with is recognized by Owners Jennifer Dinatally, Realtor, and Frank Ramos, Broker/Owner, as they testified to her consistent contributions to brokerage Realtors by providing the support, reminders, and caffeine they need to build their businesses. "Frank and I could not be more grateful for all of Carrie's hard work and dedication over the years. She has truly been an integral part of our team's growth and success. We are excited to see how we grow together going forward!" Dinatally said.

Key Points: 
  • WYOMISSING, Pa., May 2, 2024 /PRNewswire-PRWeb/ -- Carrie Naylor, Office Administrator for United Real Estate Strive 212 has recently been promoted to Office Manager.
  • This achievement comes after working 5 dedicated years with the brokerage as an Administrator despite being visually impaired.
  • Upon assuming the role of Office Manager, Carrie Naylor expressed profound excitement and gratitude for the opportunity to elevate her career to new heights.
  • "As I welcome this new chapter as Office Manager at United Real Estate Strive 212, I am overwhelmed with gratitude for the unwavering support of my colleagues, mentors, and the entire United Real Estate Strive 212 family.

MYRA VISION'S CALIBREYE™ TITRATABLE GLAUCOMA THERAPY™ SURGICAL SYSTEM SHOWCASED AT OPHTHALMOLOGY CONFERENCES, RECEIVING BEST PAPER AWARD AND RECOGNITION OF FUTURE PROMISE IN GLAUCOMA CARE

Retrieved on: 
среда, мая 1, 2024
Glaucoma surgery, Sale, University, Moran Eye Center, Lecture, TGT, Refractive surgery, Hospital, Safety, Research, Cataract, Paratriathlon, IOP, Manchester Royal Eye Hospital, NCT, Biomaterial, ASCRS, Intraocular pressure, Patient, Society, Physician, ICGS, EGS, Glaucoma, Trabeculectomy, Moorfields Eye Hospital, ARVO, Medical device

Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.

Key Points: 
  • Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.
  • The Calibreye shunt is designed to deliver an adjustable solution to control IOP in patients requiring low IOP.
  • While these devices have demonstrated an improvement in complication rates, achieving the IOP reductions necessary for these glaucoma patients remains challenging.
  • The Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System is for investigational use only and is not for sale in the U.S. or outside the U.S.

Stealth BioTherapeutics Announces Participation at Upcoming Ophthalmology Conferences

Retrieved on: 
среда, мая 1, 2024
FDA, Congress, AMD, Vance DeGeneres, Safety, OIS, Pharmacokinetics, The Company, Research, RWC, Stealth, ReNEW Schools, Paratriathlon, Season, ARVO, Pharmaceutical industry

At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Company will present a poster titled, "Next-generation Ocular Topical SBT-272 Demonstrates Optimized Retina Tissue Exposure: Building Upon Elamipretide for Treating Dry AMD."

Key Points: 
  • At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Company will present a poster titled, "Next-generation Ocular Topical SBT-272 Demonstrates Optimized Retina Tissue Exposure: Building Upon Elamipretide for Treating Dry AMD."
  • RWC is being held May 9-12 at the Fort Lauderdale Marriott Harbor Beach Hotel.
  • The upcoming presentations emphasize Stealth's commitment to develop its mitochondrial targeted investigational products to address the bioenergetic deficit contributing to disease pathology and vision loss in dry AMD.
  • Stealth is also advancing preclinical development of bevemipretide (SBT-272) for topical application, with Phase 1 initiation expected around year-end.

Eye health survey uncovers Canadians' concerns about recent symptoms affecting their eyes & vision: Canadian Ophthalmological Society

Retrieved on: 
среда, мая 1, 2024
Education, AMD, Vance DeGeneres, Cataract, Sport, Diabetic retinopathy, Diabetes, Artificial intelligence, Eye, Screen time, Paratriathlon, Hockey, Eye injury, Glaucoma, Agriculture

TORONTO, May 1, 2024 /CNW/ - In time for Vision Health Month this May, the Canadian Ophthalmological Society, the national authority on eye and vision care in Canada, has released a new survey to assess Canadians' awareness, understanding, and concerns around eye and vision health.

Key Points: 
  • TORONTO, May 1, 2024 /CNW/ - In time for Vision Health Month this May, the Canadian Ophthalmological Society, the national authority on eye and vision care in Canada, has released a new survey to assess Canadians' awareness, understanding, and concerns around eye and vision health.
  • Of the four leading eye diseases affecting vision, cataracts and glaucoma are still the most commonly known among Canadians.
  • "While the survey reveals increased awareness, it also highlights significant concerns and alarming symptoms experienced by Canadians over the past two years, emphasizing the necessity for comprehensive eye health education and regular eye exams."
  • To learn more about the four major eye diseases and get information on overall eye health, visit seethepossibilities.ca.

Ora, Inc. to showcase latest technologies and research at ARVO 2024, convene groundbreaking ophthalmic symposium Dry Horizons

Retrieved on: 
среда, мая 1, 2024
Paratriathlon, Patient, AI, Research, Partnership, Film festival, Retina, MPH, Siesta Key (TV series), Season, ARVO, Pharmaceutical industry

BOSTON, May 1, 2024 /PRNewswire/ -- Ora, Inc., the world's leading partner for ophthalmic pharmaceutical and device development, today announced its participation as a major exhibitor in the Association for Research in Vision and Ophthalmology (ARVO) 2024 conference (May 5-9), and as host and convener of the Dry Horizons Symposium (May 3) in partnership with Ophthalmology Innovation Source. Both events will take place in Seattle.

Key Points: 
  • "Team Ora is thrilled to be heading to ARVO which sets the benchmark as the premier showcase for the latest advancements in ophthalmic translational research," stated Stuart B. Abelson, President, CEO, and Chairman of Ora.
  • Just two days before the start of ARVO, Ora will co-present the first-ever Dry Horizons Symposium with Ophthalmology Innovation Source.
  • At ARVO, Ora will occupy booth #1630, which will feature Ora's people, processes and technologies that together increase the likelihood of success for ophthalmic research programs around the globe.
  • Ora will also be exhibiting a robust slate of original research presentations at ARVO as detailed in the schedule below.

EQS-News: Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)

Retrieved on: 
пятница, мая 3, 2024
AMD, Blood, Risk, Commercial, Swissmedic, Ranibizumab, Teva, Paratriathlon, Partnership, Health Canada, Visual impairment, Growth, Retina, Patient, Macular degeneration, Marketing, CBO, Quality of life, VEGF, NAMD, Pharmaceutical industry

Press release // April 11, 2024

Key Points: 
  • Press release // April 11, 2024
    Commercial launch opens up additional key markets in Europe and North America, making FYB201 available in a total of 17 countries worldwide
    Munich, Germany – Formycon AG (FSE: FYB) and Bioeq AG announce the commercial launch of FYB201, a biosimilar to Lucentis®1(Ranibizumab), in Canada and Switzerland.
  • The launch follows the marketing authorization granted by Health Canada under the trademark RanoptoTM2and Swissmedic under the trademark Ranivisio®3.
  • FYB201 was developed by Bioeq AG, a joint venture between Formycon AG and Polpharma Biologics Group BV.
  • In Canada and Switzerland, FYB201 has been approved for the treatment of age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases.

Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on: 
четверг, мая 2, 2024
FDA, Efficacy, Inflammation, DSM-IV codes, C5, Research, Abstract, Geographic atrophy, Paratriathlon, Primate, Sodium iodate, Immunoassay, AAV, Retina, ONL, Patient, Neurology, PALO, Kriyā, Mouse, Annual general meeting, Therapy, ARVO, Vaccine

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced three presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.

Key Points: 
  • PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced three presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.
  • Kriya’s pipeline includes gene therapies across several therapeutic areas including ophthalmology, metabolic disease and neurology.
  • Broad coverage was achieved from the injection site to the posterior pole, including the macula and retina.
  • The study demonstrates, in a dose dependent manner, the potential of AAV.CR2-CR1 to preserve the photoreceptor-containing outer nuclear layer (ONL).

Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting

Retrieved on: 
понедельник, апреля 22, 2024
Corneal opacity, AAV2, Nanopore, Rabbit, Immortalised cell line, Genomics, LTR, CRISPR, Genetic engineering, Abraxis BioScience, Infection, Gene, RNA, Recurrence, HeLa, Paratriathlon, Cell, HSK, AAV, Vero cell, Research, Pterygopalatine ganglion, FACS, PCR, Disease, DNA, Therapy, Viral load, HIV-1, Society, CDS, Gag, ICP0, Genome, Herpes simplex keratitis, LAT, Orientation, Annual general meeting, Edema, Valaciclovir, SAN, Vaccine

Herpes Simplex Keratitis (HSK), caused by the infection of herpes simplex virus type 1 (HSV-1) in the cornea, is a major cause of blindness worldwide.

Key Points: 
  • Herpes Simplex Keratitis (HSK), caused by the infection of herpes simplex virus type 1 (HSV-1) in the cornea, is a major cause of blindness worldwide.
  • Although current anti-HSV-1 therapies interfere with viral DNA replication, they do not eliminate HSV-1 reservoirs or prevent recurrence.
  • CRISPR/Cas-mediated gene editing can potentially address the underlying causes of the disease by directly eliminating the latent HSV-1 reservoirs.
  • The 440 guide RNA pairs formed with these 42 PlmCasX guide RNAs were tested in tissue culture for DNA excision efficiency.